NEUSTAR
14.1.2020 09:02:07 CET | Business Wire | Press release
Neustar® , Inc., a global information services company and leader in identity resolution, today announced the release of UltraThreat Feeds, a new service that provides its enterprise customers with access to real-time threat data to help them better identify cyber threats as they evolve. Designed by Neustar’s renowned security experts and leading academic researchers, the service – unique to Neustar – enables security and threat intelligence teams of all sizes to access threat feeds based on analysis and observations curated from Neustar’s expansive DNS, OneID and IP decisioning data.
Incorporating proprietary data derived from Neustar’s Security Portfolio & OneID identity resolution platform, UltraThreat Feeds can be ingested into a client’s existing platform to deliver superior threat data and provide valuable insights to unique and developing threats in near real-time.
“With the average cost of a data breach now at nearly $4 million, enterprises are investing significant resources into threat intelligence solutions to better defend themselves. A key change is enabling network and application security tools with improved real-time awareness of active threats,” said Rodney Joffe, security CTO, senior technologist and fellow at Neustar. “For example, SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls all require threat data to power their security functions to detect and block malicious actors. Neustar’s UltraThreat Feeds service delivers deep, rich threat data, giving users the power to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks.”
UltraThreat Feeds enable Neustar customers to identify:
- Malicious Domain Generation Algorithms (“DGAs”) – When malicious actors register one of the thousands of domains that are created by the DGAs within their malware, and that then allow the actors to control infected hosts from their Command and Control Servers (C2).
- Suspicious DNS Tunneling Attempts – When Domains leverage the DNS protocol to create a “tunnel” to exfiltrate data past customers’ security measures.
- Newly Observed Domains – When a Domain with little or no history is suddenly active, which presents increased risk.
- Domain Updates (Nameserver or Hosting IP Address) – When there are indications that a domain has been hijacked.
- Domain Spoofing (Business Email Compromise) – When fake online personas trick victims into making fraudulent transactions by imitating or resembling legitimate domains.
Neustar’s UltraThreat Feeds service has an advantage over competitors, thanks to the availability of its own unique data assets, including DNS data exhaust collected from the more than 100 billion queries received from 30 globally distributed nodes every day and supplemented by the IP address intelligence and analytics processed across Neustar’s product suite. Combined with behavioural analysis and pattern-based research, this advantage enables Neustar to derive truly unique insights into malicious activity. With insight gained from Neustar’s globally distributed authoritative and recursive DNS network, Neustar OneID, IP Intelligence geolocation and risk data, UltraThreat Feeds can provide a proprietary view of global threats to help identify and stop bad traffic, both inbound and outbound.
"With increasing attacker sophistication, and renewed aggression from nation-state adversaries focused on corporate espionage, many organisations are trying to find out how to properly leverage these [threat intelligence] services to protect themselves," wrote Forrester analysts Josh Zelonis and Joseph Blankenship in the report, The Forrester Tech Tide™: Zero Trust Threat Detection And Response, Q1 2019.
For more technical details on Neustar UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultra-threat-detection-feeds .
-ENDS-
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: www.home.neustar .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
